Insider trade

Director exercised or converted 75 BIO derivative securities

Traded Sep 1, 2026 · Filed Sep 3, 2026

Bio-Rad LaboratoriesBIO

75
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 1, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 3, 2026

DirectorOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001924980-26-000002

Filed / recorded

Sep 3, 2026, 9:38 PM UTC

Added to OQRO

Oct 6, 2026, 4:40 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

BIO-RAD LABORATORIES, INC.

Issuer CIK

12208

Ticker

BIO BIO.B

Reporting person

Schwartz Allison

Relationship

Director

Security

Restricted Stock Units

Table

Derivative (Table II)

Transaction date

Sep 1, 2026

Transaction code

M

Shares / units

75

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

75

Ownership form

Direct

Amendment

No

Footnotes from the filing

Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
On September 1, 2023, the reporting person was granted 298 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.